TGFB1 and osteosarcoma: (110) continuously exposed NK cells to low-dose TGF-β and IL2 in vitro, thereby alleviating the degree of immunosuppression in the canine osteosarcoma microenvironment, which might be applied to the treatment of human NK cells in the future.